Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/BOR.0000000000000725 http://scihub22266oqcxt.onion/10.1097/BOR.0000000000000725 32675715!ä!32675715 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32675715&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Opin+Rheumatol 2020 ; 32 (5): 434-440 Nephropedia Template TP {{tp|p=32675715|t=2020. Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases |pdf=|usr=}}{{32675715}} gab.com Text Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases JO: Curr Opin Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=32675715 #FOAvip PURPOSE OF REVIEW: The novel coronavirus 2019 (COVID-19) pandemic is of special concern for patients with immune-mediated inflammatory disease (IMID) and those who care for them because of the potential for worse outcomes. This article analyzes peer-reviewed research on the epidemiology and outcomes of COVID-19 in those with IMID. RECENT FINDINGS: Published literature on approximately 1400 patients was included from rheumatology, gastroenterology, and dermatology. Data suggest that those who are older and have comorbidities have poorer outcomes. This is consistent with the reports from the general population of patients with COVID-19. Adjusted analyses from the largest published studies demonstrate independent effects of systemic glucocorticoids, as well as age and comorbidities with poorer COVID-19 outcomes (SECURE-IBD registry, n = 525; COVID-19 Global Rheumatology Alliance registry, n = 600); biologic or targeted synthetic disease-modifying antirheumatic drug therapy has not been associated with more severe outcomes. These early results will require validation in population-based studies as more data becomes available. SUMMARY: Current data suggest that similar to the general population, age, and comorbidities are risk factors for poorer COVID-19 outcomes in patients with IMID. Additional research is needed to quantify outcomes and risk across rheumatic disease types, comorbidities, and immunosuppressive drugs. Twit Text FOAVip Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases ????Curr Opin Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=32675715 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32675715 #FOAvip English Wikipedia <ref>{{Cite pmid|32675715}}</ref> Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases #MMPMID32675715 Gianfrancesco M; Yazdany J; Robinson PC Curr Opin Rheumatol 2020[Sep]; 32 (5): 434-440 PMID32675715show ga PURPOSE OF REVIEW: The novel coronavirus 2019 (COVID-19) pandemic is of special concern for patients with immune-mediated inflammatory disease (IMID) and those who care for them because of the potential for worse outcomes. This article analyzes peer-reviewed research on the epidemiology and outcomes of COVID-19 in those with IMID. RECENT FINDINGS: Published literature on approximately 1400 patients was included from rheumatology, gastroenterology, and dermatology. Data suggest that those who are older and have comorbidities have poorer outcomes. This is consistent with the reports from the general population of patients with COVID-19. Adjusted analyses from the largest published studies demonstrate independent effects of systemic glucocorticoids, as well as age and comorbidities with poorer COVID-19 outcomes (SECURE-IBD registry, n = 525; COVID-19 Global Rheumatology Alliance registry, n = 600); biologic or targeted synthetic disease-modifying antirheumatic drug therapy has not been associated with more severe outcomes. These early results will require validation in population-based studies as more data becomes available. SUMMARY: Current data suggest that similar to the general population, age, and comorbidities are risk factors for poorer COVID-19 outcomes in patients with IMID. Additional research is needed to quantify outcomes and risk across rheumatic disease types, comorbidities, and immunosuppressive drugs. |*Betacoronavirus[MESH] |Antirheumatic Agents/therapeutic use[MESH] |COVID-19[MESH] |Comorbidity[MESH] |Coronavirus Infections/complications/*epidemiology/therapy[MESH] |Humans[MESH] |Pandemics[MESH] |Pneumonia, Viral/complications/*epidemiology/therapy[MESH] |Rheumatic Diseases/*complications/drug therapy[MESH] |Risk Factors[MESH]Epidemiology and outcomes of novel coronavirus 2019 in patients with (epmc).pdf DeepDyve Pubget Overpricing